AURX Nuo Therapeutics, Inc.
Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1091596 · Fiscal year ends 12/31
Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY123.7%
TTM net income YoY2.0%
TTM EPS YoY—
Revenue 3-yr CAGR308.7%
Net income 3-yr CAGR—
Margins
Gross margin70.4%
Operating margin-98.3%
Net margin-93.1%
FCF margin-44.6%
EBITDA margin-95.5%
Returns
ROE-1,032.5%
ROA-133.3%
ROIC (approx.)—
Asset turnover1.43x
Leverage & solvency
Liabilities / assets121.8%
Debt / equity—
Current ratio1.16x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.38x
Accruals ratio-82.1%
Payout ratio—
Capex / revenue8.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $3.31M | $1.37M |
| Cost of revenue | $1.10M | $302,842 |
| Gross profit | $2.22M | $1.06M |
| SG&A expense | $4.73M | $3.52M |
| Operating income | -$2.52M | -$2.46M |
| Pretax income | -$2.51M | -$2.32M |
| Income tax | $0 | $0 |
| Net income | -$2.51M | -$2.32M |
| EBITDA | -$2.43M | -$2.43M |
| EPS (basic) | -0.05 | -0.05 |
| EPS (diluted) | — | — |
| Balance sheet | ||
| Cash & equivalents | $548,946 | $283,714 |
| Receivables | $561,667 | $248,205 |
| Inventory | $213,761 | $150,442 |
| Current assets | $1.38M | $841,546 |
| PP&E, net | $366,315 | $177,022 |
| Total assets | $1.85M | $1.19M |
| Current liabilities | $1.31M | $578,451 |
| Total liabilities | $2.80M | $675,796 |
| Shareholders' equity | -$956,559 | $513,712 |
| Shares outstanding | 48.18M | 46.82M |
| Cash flow statement | ||
| Operating cash flow | -$864,971 | -$2.23M |
| Capital expenditure | $274,756 | $154,962 |
| Free cash flow | -$1.14M | -$2.39M |
| Investing cash flow | -$274,756 | -$154,962 |
| Financing cash flow | $1.40M | $1.74M |
| Depreciation & amortization | $85,463 | $23,022 |
| Stock-based compensation | $85,986 | $56,652 |
Free plan shows the latest 2 periods; Pro shows all 15 🔒
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.